<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377466</url>
  </required_header>
  <id_info>
    <org_study_id>200719</org_study_id>
    <nct_id>NCT02377466</nct_id>
  </id_info>
  <brief_title>A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor</brief_title>
  <acronym>NEWBORN-1</acronym>
  <official_title>Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's primary objective is to demonstrate the superiority of retosiban to prolong
      pregnancy and improve neonatal outcomes compared with placebo. It is a Phase III,
      randomized, double-blind, parallel-group, multicenter study and will be conducted in
      approximately 900 females, aged 12 to 45 years, with an uncomplicated, singleton pregnancy
      and intact membranes in preterm labor between 24^0/7 and 33^6/7 weeks of gestation. Eligible
      maternal subjects will be randomly assigned in a 1:1 ratio to receive either retosiban IV
      infusion or placebo IV infusion over 48 hours. If not previously administered, antenatal
      corticosteroid treatment should be administered as either (1) two 12-mg doses of
      betamethasone given intramuscularly 24 hours apart or (2) four 6-mg doses of betamethasone
      administered intramuscularly every 12 hours. A single rescue course of antenatal
      corticosteroids is permitted if the antecedent treatment was at least 7 days prior to study
      enrolment. Investigators have discretion to use a standardized regimen of magnesium
      sulphate, as well as intrapartum antibiotic prophylaxis for perinatal group B streptococcal
      infection. Prior to randomization, each subject will be stratified by progesterone treatment
      and gestational age. The progesterone strata will consist of subjects on established
      progesterone therapy or subjects not on established progesterone therapy at Screening. The
      study will comprise 6 phases: Screening, Inpatient Randomized Treatment, Post Infusion
      Assessment, Delivery, Maternal Post-Delivery Assessment, and Neonatal Medical Review. The
      duration of any subject's (maternal or neonatal) participation in the study will be variable
      and dependent on gestational ages (GA) at study entry and the date of delivery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 29, 2016</start_date>
  <completion_date type="Anticipated">May 14, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to delivery or treatment failure, whichever occurs first</measure>
    <time_frame>From the start of study treatment administration (Day 1) until delivery (Assessed up to 20 weeks)</time_frame>
    <description>The time to delivery will be assessed from the start of study treatment administration in the in-patient Randomized Treatment Phase until delivery. The time to treatment failure will be calculated from the start of study treatment administration to the time to administration of any putative tocolytic medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of neonates with any diagnosis from the neonatal morbidity and mortality</measure>
    <time_frame>Up to 28 days after the estimated date of delivery (EDD) of 40^0/7 weeks</time_frame>
    <description>The composite consists of the following: fetal or neonatal death, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis, meningitis, retinopathy of prematurity, intraventricular hemorrhage, white matter injury, and cerebellar hemorrhage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of births prior to 37^0/7 weeks' gestation</measure>
    <time_frame>Up to 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of births at term (37^0/7 to 41^6/7 weeks' gestation)</measure>
    <time_frame>Up to 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of neonatal hospital stay</measure>
    <time_frame>Up to 28 days after the EDD of 40^0/7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of births prior to 32^0/7 weeks gestation</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of births prior to 28^0/7 weeks' gestation</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of births within &lt;=7 days</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of births within &lt;=48 hours</measure>
    <time_frame>Up to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of births within &lt;=24 hours</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of neonates with any of the co-primary composite neonatal morbidity and mortality, excluding respiratory distress syndrome</measure>
    <time_frame>Up to 28 days after the EDD of 40^0/7 weeks</time_frame>
    <description>Fetal or neonatal death, bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis, meningitis, retinopathy of prematurity, intraventricular hemorrhage, white matter injury, and cerebellar hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of neonates with each individual component of the composite neonatal morbidity and mortality endpoints</measure>
    <time_frame>Up to 28 days after the EDD of 40^0/7 weeks</time_frame>
    <description>Fetal or neonatal death, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis or isolated perforation, sepsis, meningitis, retinopathy of prematurity, intraventricular hemorrhage, white matter injury, and cerebellar hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal admission to a specialized care unit and length of stay</measure>
    <time_frame>Up to 28 days after the EDD of 40^0/7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Newborn hospital readmission and length of stay</measure>
    <time_frame>Up to 28 days after the EDD of 40^0/7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory surgery</measure>
    <time_frame>Up to 28 days after the EDD of 40^0/7weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal: Number of mothers with reported Adverse Events (AEs) and serious AEs (SAEs) during and after IV retosiban treatment compared with placebo</measure>
    <time_frame>6 weeks (+/- 2 weeks after delivery)</time_frame>
    <description>Maternal incidence of reported AEs and SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal: Number of mothers with significant changes in vital signs measurements during and after IV retosiban treatment compared with placebo</measure>
    <time_frame>6 weeks (+/- 2 weeks after delivery)</time_frame>
    <description>Vital signs measurements including blood pressure, pulse rate and temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal: Number of mothers with significant changes in clinical laboratory tests during and after IV retosiban treatment compared with placebo</measure>
    <time_frame>6 weeks (+/- 2 weeks after delivery)</time_frame>
    <description>Clinical laboratory tests include routine hematology, chemistry and liver function tests (LFTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal: Incidence of mothers discontinuing study treatment due to clinical and laboratory toxicities</measure>
    <time_frame>Up to 48 hours after start of IV infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal: Incidence of mothers scoring 12 or higher on the Edinburgh Postnatal Depression Scale (EPDS)</measure>
    <time_frame>6 weeks (+/- 2 weeks after delivery)</time_frame>
    <description>The EPDS is a self reported assessment of depression validated for both the antenatal and postnatal periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal: Incidence of mothers reporting AEs of special interest during and after IV retosiban treatment compared with placebo</measure>
    <time_frame>6 weeks (+/- 2 weeks after delivery)</time_frame>
    <description>Maternal AEs of special interest include death, chorioamnionitis and its complications, placental abruption, postpartum hemorrhage, retained placenta and pulmonary edema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal: Incidence of reported AEs and SAEs during and after IV retosiban treatment compared with placebo</measure>
    <time_frame>Screening until delivery (assessed up to 20 weeks)</time_frame>
    <description>Fetal incidence of reported AEs and SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal acidosis</measure>
    <time_frame>Screening until delivery (assessed up to 20 weeks)</time_frame>
    <description>Fetal acidosis will be assessed during and after IV infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal AEs of special interest during and after IV retosiban treatment compared with placebo</measure>
    <time_frame>Screening until delivery (assessed up to 20 weeks)</time_frame>
    <description>Fetal AEs of special interest include intrauterine fetal demise, category II or III fetal heart rate tracing and fetal inflammatory response syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Apgar scores</measure>
    <time_frame>On the day of birth</time_frame>
    <description>Apgar scores will be calculated at 1 and 5 minutes after birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal growth</measure>
    <time_frame>On the day of birth and at discharge from hospital</time_frame>
    <description>Growth parameters include weight, length and head circumference at birth and at discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal: Incidence of reported AEs and SAEs</measure>
    <time_frame>Birth until 28 days after estimated due date (assessed up to 20 weeks)</time_frame>
    <description>Neonatal incidence of reported AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal: Incidence of AEs of special interest</measure>
    <time_frame>Birth until 28 days after estimated due date (assessed up to 20 weeks)</time_frame>
    <description>Neonatal AEs of special interest include neonatal death, asphyxia, infections, respiratory distress syndrome, hypotension, intraventricular/periventricular leukomalacia, bronchopulmonary dysplasia, neonatal acidosis, hyperbilirubinemia, necrotizing enterocolitis and hypoxic ischemic encephalopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal and neonatal health care resource use associated with preterm labor and preterm delivery</measure>
    <time_frame>Up to 28 days after the EDD of 40 weeks</time_frame>
    <description>Maternal hospital admission and resource use, Neonatal interventions of interest (e.g., parenteral nutrition, surfactants, blood products), procedures (e.g., imaging, such as ultrasound and computed tomography), and surgical procedures, Neonatal hospital admission and resource use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retosiban clearance and volume of distribution and the effect of covariates on these parameters</measure>
    <time_frame>From start of infusion on Day 1 until up to 60 hours later</time_frame>
    <description>The information on the pharmacokinetics of retosiban in pregnant women, including the effect of covariates such as age, weight, race/ethnicity, and gestational age on retosiban clearance and volume of distribution will be obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to delivery</measure>
    <time_frame>From the start of study treatment administration (Day 1) until delivery (assessed up to 20 weeks)</time_frame>
    <description>The time to delivery will be assessed from the start of study treatment administration in the in-patient randomized treatment phase until delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From the start of study treatment (Day 1) until administration of a putative tocolytic (assessed up to 20 weeks)</time_frame>
    <description>Treatment failure is defined as the administration of any putative tocolytic medication, such as calcium-channel blockers, NSAIDs or beta-agonists. The time to treatment failure is defined as the time from the start of the study treatment administration in the inpatient randomized phase until a putative tocolytic is administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women receiving any putative tocolytic</measure>
    <time_frame>From the start of study treatment administration (Day 1) until administration of a putative tocolytic (assessed up to 20 weeks)</time_frame>
    <description>Putative tocolytics include calcium-channel blockers, NSAIDs or beta-agonists.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Obstetric Labour, Premature</condition>
  <arm_group>
    <arm_group_label>Retosiban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo control will be a normal saline (0.9% sodium chloride [NaCl]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retosiban IV infusion</intervention_name>
    <description>Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).</description>
    <arm_group_label>Retosiban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV infusion</intervention_name>
    <description>0.9% NaCl matched for the retosiban loading dose and continuous infusion rates</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent is required prior to a subject's
             participation in the study and the performance of any protocol specific procedures.
             Adolescents aged 12 to 17 years must provide written agreement to participate in the
             study in accordance with applicable regulatory and country or state requirements.
             Subjects will also be asked to sign a release for medical records at the time of
             consenting to allow access to both the maternal and neonatal records including
             information about delivery and infant care as well as information collected prior to
             the consent having been signed.

          -  Females aged 12 to 45 years, with an uncomplicated, singleton pregnancy and intact
             membranes in preterm.

          -  Gestational age between 24 and 33 weeks as determined by (1) known fertilization
             date, either in vitro fertilization or intrauterine insemination, (2) last menstrual
             period confirmed by the earliest ultrasound prior to 24 weeks gestation, or (3) the
             earliest ultrasound alone prior to 24 weeks gestation, whichever is the most accurate
             method available for each subject. In situations where prenatal ultrasound records
             are not available at the time the subject presents, the investigator will make every
             effort to obtain these records (either via computer records, directly from the
             subject's primary care obstetrician, or via telephone). However, in cases in which
             these records are not readily available (e.g., off hours, holiday), it is within the
             investigator's discretion to use GA based on a verbal history from the subject with
             the intent of getting confirmation from the medical records as soon as possible.

          -  Females must be diagnosed with preterm labor according to both of the following
             criteria: a) Regular uterine contractions at a rate of &gt;=4 contractions of at least
             30 seconds' duration during a 30-minute interval confirmed by tocodynamometry and at
             least 1 of the following, b) Cervical dilation &gt;=2 centimeter (cm) and &lt;=4 cm by
             digital cervical examination or c) If &lt;2 cm dilation by digital cervical examination,
             a cervical change consisting of an increase of at least 25% effacement or 1-cm
             dilation.

          -  Current or past tocolytic treatment as follows: a) Subjects in whom tocolytic
             treatment has not been initiated prior to consent are eligible for the study, b)
             Transferred or referred subjects for whom parenteral magnesium sulfate treatment has
             been started before Screening are eligible provided they meet all eligibility
             criteria, c) Subjects receiving a prohibited tocolytic in this study are eligible
             only if the treatment is stopped before randomization and provided they meet all
             eligibility criteria, d) Subjects with a historical failure of a tocolytic treatment
             in a previous episode of preterm labor during the current pregnancy are eligible
             provided they meet all eligibility criteria.

        Exclusion Criteria:

          -  Fever with a temperature &gt;100.4 degree Fahrenheit (38 degree centigrade) for more
             than 1 hour or &gt;=101 degree Fahrenheit (38.3 degree centigrade) in the 24 hours prior
             to the start of study treatment.

          -  Women with maternal-fetal conditions that potentially necessitate the need for
             delivery, such as pre-eclampsia or fetal compromise.

          -  A fetus with any diagnosis, condition, treatment, or other factor that in the opinion
             of the investigator has the potential to affect or confound assessments of efficacy
             or safety (for example: nonreassuring fetal status, intrauterine growth restriction,
             major congenital anomaly).

          -  Preterm premature rupture of membranes.

          -  Women with any confirmed or suspected contraindication to prolongation of pregnancy,
             such as placental abruption, chorioamnionitis, or placenta previa.

          -  Evidence of polyhydramnios (AFI &gt;25 cm) or oligohydramnios (AFI &lt;5 cm).

          -  Women with co-morbid medical or obstetric conditions that in the opinion of the
             investigator have the potential to complicate the pregnancy course and outcomes, such
             as uncontrolled hypertension or uncontrolled diabetes (if known, history of
             glycosylated hemoglobin &gt;8% at any time during pregnancy), or compromise the safety
             of the subject, such as underlying cardiovascular disorder (specifically ischemic
             cardiac disease, congenital heart disease, pulmonary hypertension, valvular heart
             disease, arrhythmias, and cardiomyopathy).

          -  Women with a history of substance abuse during the pregnancy or urine drug screen
             positive for cocaine, phencyclidine (PCP), methamphetamine, or amphetamine.

          -  Women in whom the combination of history and screening test results is suggestive of
             abuse or dependency that may have the potential to complicate the pregnancy outcome.

          -  Women with any diagnosis, condition, treatment, or other factor that, in the opinion
             of the investigator, has the potential to affect or confound assessments of efficacy
             or safety.

          -  Current active liver or biliary disease (with the exception of Gilbert's syndrome or
             asymptomatic gallstones or otherwise stable chronic liver disease per investigator
             assessment).

          -  History of sensitivity to any of the investigational products (IPs) or components
             thereof or a history of drug or other allergy that, in the opinion of the
             investigator or GlaxoSmithKline/ Pharmaceutical Product Development (GSK/PPD) medical
             monitor, contraindicates the subject's participation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond Heights</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>989-3126</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyazaki</city>
        <zip>889-1692</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>904-2293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tochigi</city>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>February 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spontaneous Preterm Labor</keyword>
  <keyword>GSK221149</keyword>
  <keyword>Retosiban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
